A health crisis has erupted in Rajasthan following the tragic deaths of several women during childbirth in Kota, prompting swift action against Jackson Laboratories. The state health department discovered that a batch of Oxytocin injections manufactured by the company was substandard, leading to disciplinary proceedings against the firm. Gayatri Rathore, the Principal Secretary of Health in Rajasthan, confirmed that an immediate ban has been placed on the sale and use of the affected batch, and hospitals have been instructed to remove these injections from their inventories.
The alarm was raised after five maternal deaths in Kota, which led to an investigation by a team from the All India Institute of Medical Sciences (AIIMS). During their inquiry, experts recommended testing all medications administered to patients before attributing blame to the Oxytocin injections. Dr. Ritika Mathur, a gynecologist, expressed skepticism regarding the direct link between the injections and the deaths, noting that one deceased woman had not even received the injection.
- Immediate action against Jackson Laboratories — following substandard Oxytocin findings.
- Statewide ban on affected injections — to prevent further risks to maternal health.
- Ongoing investigation into maternal deaths — focusing on broader medical practices and protocols.
Authorities discovered that the tested samples of Oxytocin lacked the required active ingredient, raising serious concerns within the Rajasthan Medical Department. The state Drug Control authorities are now investigating whether the same batch was distributed to other hospitals or sold in the open market. In total, over 12,500 women were reportedly treated with these injections during childbirth procedures, making the situation even more alarming.
As investigations unfold, officials have seized significant quantities of the failed batch, including 2,479 injections from Kota Medical College and others from local hospitals. Devendra Kumar Garg, the Assistant Drug Controller, emphasized that the absence of the active ingredient does not directly correlate with the maternal deaths, urging a thorough examination of all factors involved in the cases. The focus is now on ensuring that similar incidents do not occur in the future, as the state grapples with the implications of this health scare.
